X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (37) 37
immunotherapy (35) 35
nivolumab (35) 35
humans (29) 29
cancer (18) 18
oncology (18) 18
ipilimumab (16) 16
male (16) 16
melanoma (15) 15
apoptosis (14) 14
care and treatment (13) 13
middle aged (13) 13
pembrolizumab (13) 13
aged (12) 12
female (12) 12
programmed cell death 1 receptor - antagonists & inhibitors (12) 12
case report (11) 11
safety (11) 11
anti-programmed death-1 (10) 10
antibodies, monoclonal - adverse effects (10) 10
antineoplastic agents - therapeutic use (10) 10
dermatology (10) 10
medicine, research & experimental (10) 10
therapy (10) 10
adult (9) 9
aged, 80 and over (9) 9
anti-programmed cell death-1 (9) 9
antibodies, monoclonal - therapeutic use (9) 9
antineoplastic agents - adverse effects (9) 9
chemotherapy (9) 9
metastasis (9) 9
metastatic melanoma (8) 8
open-label (8) 8
treatment outcome (8) 8
advanced melanoma (7) 7
antigens (7) 7
drug therapy (7) 7
expression (7) 7
patients (7) 7
research (7) 7
antibodies, monoclonal, humanized - adverse effects (6) 6
antibodies, monoclonal, humanized - therapeutic use (6) 6
antibody (6) 6
antineoplastic agents, immunological - adverse effects (6) 6
cancer therapies (6) 6
development and progression (6) 6
health aspects (6) 6
immunotherapy - methods (6) 6
lung cancer (6) 6
medicine, general & internal (6) 6
melanoma - drug therapy (6) 6
programmed cell death 1 receptor - immunology (6) 6
usage (6) 6
young adult (6) 6
adverse events (5) 5
anti-pd-1 (5) 5
anti-programmed death-1 antibody (5) 5
anti-programmed-death-1 (5) 5
biochemistry (5) 5
cell death (5) 5
immune checkpoint (5) 5
immune checkpoint inhibitors (5) 5
monoclonal antibodies (5) 5
neoplasms. tumors. oncology. including cancer and carcinogens (5) 5
pd-1 blockade (5) 5
risk factors (5) 5
skin neoplasms - drug therapy (5) 5
survival (5) 5
t cells (5) 5
analysis (4) 4
animals (4) 4
anti-programmed cell death-1 antibody (4) 4
anti-programmed cell death-1 therapy (4) 4
antibodies (4) 4
articles (4) 4
biotechnology & applied microbiology (4) 4
cell lung-cancer (4) 4
complications and side effects (4) 4
diabetes (4) 4
immune checkpoint blockade (4) 4
immunology (4) 4
lymphocytes (4) 4
management (4) 4
neoplasm metastasis (4) 4
non-small cell lung cancer (4) 4
pd-1 (4) 4
programmed cell death 1 receptor - metabolism (4) 4
respiratory system (4) 4
t-cells (4) 4
anti-pd-l1 antibody (3) 3
antineoplastic agents (3) 3
antineoplastic agents - pharmacology (3) 3
antineoplastic agents, immunological - therapeutic use (3) 3
article (3) 3
association (3) 3
blockade (3) 3
brain metastases (3) 3
cancer research (3) 3
carcinoma, renal cell - drug therapy (3) 3
clinical activity (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


JOURNAL OF THORACIC ONCOLOGY, ISSN 1556-0864, 12/2019, Volume 14, Issue 12, pp. 2071 - 2083
Introduction: Programmed cell death-1 (PD-1) inhibitors effectively treat NSCLC and prolong survival. Robust biomarkers for predicting clinical benefits of... 
Biomarker | NSCLC | LUNG ADENOCARCINOMA PATIENTS | INDUCTION | CANCER | Anti-programmed death 1 therapy | BIOMARKERS | ONCOLOGY | GAGED2A | IMMUNOTHERAPY | RESPIRATORY SYSTEM | Serum antibody | Cancer-testis antigen | PD-1 | EXPRESSION | IMMUNE-CHECKPOINT BLOCKADE | T-CELLS
Journal Article
Melanoma research, ISSN 0960-8931, 04/2018, Volume 28, Issue 2, pp. 111 - 119
Journal Article
Acta Dermato-Venereologica, ISSN 0001-5555, 11/2017, Volume 97, Issue 10, pp. 1212 - 1218
Anti-programmed cell death-1 (anti-PD-1) antibody shows high therapeutic efficacy in patients with advanced melanoma. However, assessment of its therapeutic... 
NRAS | BRAF | Circulating tumour DNA | Droplet digital PCR | Anti-programmed cell death-1 antibody | Melanoma | DIGITAL PCR | melanoma | NRAS MUTATIONS | CANCER | DERMATOLOGY | METASTATIC MELANOMA | anti-programmed cell death-1 antibody | THERAPY | PLASMA | circulating tumour DNA | droplet digital PCR | RESISTANCE | NIVOLUMAB | UTILITY | Melanoma - blood | Predictive Value of Tests | Immunotherapy - methods | Skin Neoplasms - drug therapy | Circulating Tumor DNA - genetics | Proto-Oncogene Proteins p21(ras) - genetics | Humans | Middle Aged | Antibodies, Monoclonal - therapeutic use | Male | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Tomography, X-Ray Computed | Cell-Free Nucleic Acids - genetics | Drug Monitoring - methods | Skin Neoplasms - blood | Time Factors | DNA Mutational Analysis | Melanoma - genetics | Aged, 80 and over | Female | Skin Neoplasms - immunology | Treatment Outcome | Biomarkers, Tumor - blood | Antineoplastic Agents, Immunological - therapeutic use | Melanoma - immunology | Proto-Oncogene Proteins B-raf - genetics | Cell-Free Nucleic Acids - blood | Melanoma - drug therapy | Skin Neoplasms - genetics | Cell Line, Tumor | Aged | Biomarkers, Tumor - genetics | Circulating Tumor DNA - blood | Mutation | Programmed Cell Death 1 Receptor - immunology | anti-programmedcelldeath-1antibody | circulatingtumourDNA | dropletdigitalPCR
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2015, Volume 373, Issue 19, pp. 1803 - 1813
Journal Article
OncoImmunology, ISSN 2162-4011, 01/2019, Volume 8, Issue 1, p. e1524695
Colitis is a frequent, clinically-significant immune-related adverse event caused by anti-programmed death-1 (PD-1). The clinical features, timing, and... 
anti-programmed-death-1 | melanoma | Colitis | immune-related adverse events | immunotherapy | SURVIVAL | STAGE-III | IMMUNOLOGY | METASTATIC MELANOMA | TOXICITIES | ANTI-CTLA-4 | ONCOLOGY | NIVOLUMAB | ADVERSE EVENTS | IPILIMUMAB
Journal Article
Journal Article
Journal Article
Journal Article
Journal of Diabetes Investigation, ISSN 2040-1116, 11/2016, Volume 7, Issue 6, pp. 915 - 918
Journal Article